Academic Journal
Utilizing chemokines in cancer immunotherapy.
| Title: | Utilizing chemokines in cancer immunotherapy. |
|---|---|
| Authors: | Märkl F; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany., Huynh D; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Endres S; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany., Kobold S; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany. Electronic address: Sebastian.kobold@med.uni-muenchen.de. |
| Source: | Trends in cancer [Trends Cancer] 2022 Aug; Vol. 8 (8), pp. 670-682. Date of Electronic Publication: 2022 Apr 29. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101665956 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-8025 (Electronic) Linking ISSN: 24058025 NLM ISO Abbreviation: Trends Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Cambridge, MA] : Cell Press, [2015]- |
| MeSH Terms: | Immunotherapy* , Neoplasms*/therapy, Chemokines/metabolism ; Humans ; Immunotherapy, Adoptive ; Tumor Microenvironment |
| Abstract: | Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro- and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunotherapy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies. Competing Interests: Declaration of interests S.K. has received honoraria from TCR2 Inc., Novartis, BMS and GSK. S.K. and S.E. are inventors of several patents in the field of immuno-oncology. S.K. and S.E. received license fees from TCR2 Inc. and Carina Biotech. S.K. and S.E. received research support from TCR2 Inc. and Arcus Bioscience for work unrelated to the manuscript. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| Contributed Indexing: | Keywords: CAR T cells; antibodies; cancer vaccines; chemokines; inhibitors; oncolytic viruses |
| Substance Nomenclature: | 0 (Chemokines) |
| Entry Date(s): | Date Created: 20220502 Date Completed: 20220722 Latest Revision: 20220915 |
| Update Code: | 20221216 |
| DOI: | 10.1016/j.trecan.2022.04.001 |
| PMID: | 35501268 |
| Database: | MEDLINE |
| ResultId |
1 |
|---|---|
| Header |
cmedm MEDLINE 35501268 3 Academic Journal academicJournal |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=35501268 |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Utilizing chemokines in cancer immunotherapy.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AU" term="%22Märkl+F%22">Märkl F</searchLink>; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Huynh+D%22">Huynh D</searchLink>; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Endres+S%22">Endres S</searchLink>; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kobold+S%22">Kobold S</searchLink>; Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, Research Center for Environmental Health (HMGU), Neuherberg, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany. Electronic address: Sebastian.kobold@med.uni-muenchen.de. ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22101665956%22">Trends in cancer</searchLink> [Trends Cancer] 2022 Aug; Vol. 8 (8), pp. 670-682. <i>Date of Electronic Publication: </i>2022 Apr 29. ) Array ( [Name] => TypePub [Label] => Publication Type [Group] => TypPub [Data] => Journal Article; Review; Research Support, Non-U.S. Gov't ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => TitleSource [Label] => Journal Info [Group] => Src [Data] => <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101665956 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2405-8025 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224058025%22">24058025 </searchLink><i>NLM ISO Abbreviation: </i>Trends Cancer <i>Subsets: </i>MEDLINE ) Array ( [Name] => PublisherInfo [Label] => Imprint Name(s) [Group] => PubInfo [Data] => <i>Original Publication</i>: [Cambridge, MA] : Cell Press, [2015]- ) Array ( [Name] => SubjectMESH [Label] => MeSH Terms [Group] => Su [Data] => <searchLink fieldCode="MM" term="%22Immunotherapy%22">Immunotherapy*</searchLink> <br /><searchLink fieldCode="MM" term="%22Neoplasms%22">Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Neoplasms+therapy%22">therapy</searchLink><br /><searchLink fieldCode="MH" term="%22Chemokines%22">Chemokines</searchLink>/<searchLink fieldCode="MH" term="%22Chemokines+metabolism%22">metabolism</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Immunotherapy%2C+Adoptive%22">Immunotherapy, Adoptive</searchLink> ; <searchLink fieldCode="MH" term="%22Tumor+Microenvironment%22">Tumor Microenvironment</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro- and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunotherapy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies.<br />Competing Interests: Declaration of interests S.K. has received honoraria from TCR2 Inc., Novartis, BMS and GSK. S.K. and S.E. are inventors of several patents in the field of immuno-oncology. S.K. and S.E. received license fees from TCR2 Inc. and Carina Biotech. S.K. and S.E. received research support from TCR2 Inc. and Arcus Bioscience for work unrelated to the manuscript.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.) ) Array ( [Name] => SubjectMinor [Label] => Contributed Indexing [Group] => [Data] => <i>Keywords: </i>CAR T cells; antibodies; cancer vaccines; chemokines; inhibitors; oncolytic viruses ) Array ( [Name] => NumberCAS [Label] => Substance Nomenclature [Group] => ID [Data] => 0 (Chemokines) ) Array ( [Name] => DateEntry [Label] => Entry Date(s) [Group] => Date [Data] => <i>Date Created: </i>20220502 <i>Date Completed: </i>20220722 <i>Latest Revision: </i>20220915 ) Array ( [Name] => DateUpdate [Label] => Update Code [Group] => Date [Data] => 20221216 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/j.trecan.2022.04.001 ) Array ( [Name] => AN [Label] => PMID [Group] => ID [Data] => 35501268 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/j.trecan.2022.04.001
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[StartPage] => 670
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Chemokines metabolism
[Type] => general
)
[1] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[2] => Array
(
[SubjectFull] => Immunotherapy, Adoptive
[Type] => general
)
[3] => Array
(
[SubjectFull] => Tumor Microenvironment
[Type] => general
)
[4] => Array
(
[SubjectFull] => Immunotherapy
[Type] => general
)
[5] => Array
(
[SubjectFull] => Neoplasms therapy
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Utilizing chemokines in cancer immunotherapy.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Märkl F
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Huynh D
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Endres S
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kobold S
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 08
[Text] => 2022 Aug
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-electronic
[Value] => 2405-8025
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 8
)
[1] => Array
(
[Type] => issue
[Value] => 8
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Trends in cancer
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |